flip burger stock ow
guidanc cut reason period limit nt visibl guidanc revis
tune led stock give rise march low
quantum revis expect believ element
uncertainty/conservat built guidanc even pan
meat processor flag critic bottleneck protein
suppli chain refer joint expert call expect market come view
reason guid consid challeng current livestock segment
owe nt lack visibl fall back fundament forecast
stock view ca grow pet visit spike april believ visit
volum return earlier anticip trio guidanc revis
modest view flag franchis despit new launch struggl
believ could fundament chang welcom
household benefit lt pet volum spend refer pet adopt note
acknowledg econom condit still believ protein demand unlik
weaken dm em note china mexico brazil saw doubl digit growth ca
growth led ca asf drag reced report revenu
driven growth ca/livestock ca led apoquel cytopoint
well simparica franchis stock trio unlik peer
bayer/virbac limit stock effect us livestock growth led
poultri primarili zoamix prior quarter beef dairi weak
focu divers growth invest includ pumpkin pet
insur offer launch recent product innov mab vaccin
diagnost strategi integr offer support trio launch
inflect year diagnost integr abaxi refer lab buy
etho phoenix znlab refer growth see paw part ii
ow rais pt lower estim maintain
strong outlook expect focu shift earn rais pt
base vs multipl new ep
quarterli annual ep usd
rais usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight ow driven
new launch companion anim health
greater thrust toward biolog drug
unmet need chronic diseas pet also
expect continu effici alloc
capit done past value-ad
strong global growth faster anticip margin
expans earlier launch symparica trio valu
weak integr abaxi delay launch
symparica trio greater anticip competit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
report revenu in-lin consensu adj ep
consensu total ca grew reported/oper total
livestock segment grew reported/oper total revenu growth
reported/oper y/i
within us growth quarter companion anim grow
driven key derm portfolio apoquel cytopoint well simparica franchis
includ earli stock simparica trio us livestock growth continu led
poultri primarili zoamix previou quarter beef dairi sector
remain weak howev unlik peer like bayer virbac zoeti seem limit
stock effect
segment grew oper companion anim deliv
reported/oper livestock reported/oper start see
growth swine expand herd increas biosecur measur follow asf
lower guidanc includ revenu adjust
dilut ep reflect headwind covid-
recessionari condit fx headwind
addit simparica trio increment revenu expect vs
earlier increment revenu guid recent note challeng
newer launch incl trio near term expert call takeaway impact
companion anim livestock
expert call takeaway impact companion anim livestock
tailwind tail rise pet adopt structur growth driver
read-through bayer anim health strong result
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
